Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 10;14(4):1142.
doi: 10.3390/jcm14041142.

Management of Bulky Tumors in Cervical Cancer: Limits of the Surgical Approach

Affiliations
Review

Management of Bulky Tumors in Cervical Cancer: Limits of the Surgical Approach

María Alonso-Espías et al. J Clin Med. .

Abstract

The standard treatment for cervical tumors larger than 4 cm, known as bulky tumors, currently involves concurrent chemoradiotherapy followed by vaginal brachytherapy. However, radical surgery is an alternative option in some cases, particularly for those in which a combination of risk factors is not anticipated. Recent studies show that neoadjuvant chemotherapy may help reduce tumor size in these bulky tumors, enabling subsequent surgical intervention reducing the adverse effects derived from radiotherapy. Evidence about fertility sparing surgery in patients with bulky tumors is limited, although some retrospective studies reported good oncological outcomes when adequate tumor reduction is achieved through neoadjuvant chemotherapy. Moreover, the administration of adjuvant radiotherapy after radical surgery in patients with tumor sizes ≥ 4 cm in the final pathological report, combined with other intermediate risk factors for recurrence, remains a topic of debate. Current evidence indicates no significant differences in overall survival or disease-free survival between follow-up alone and the use of adjuvant radiotherapy in these cases, although further research is needed to refine treatment strategies for these patients. This narrative review aims to summarize the available evidence on the comprehensive management of bulky cervical tumors, addressing relevant issues and controversies in the field.

Keywords: adjuvant radiotherapy; bulky tumors; cervical cancer; neoadjuvant chemotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Pelvic magnetic resonance imaging of a bulky cervical tumor (marked with the dotted circle). The image corresponds to a 43-year-old patient diagnosed with cervical squamous cell carcinoma, with tumor dimensions of 43 × 41 × 39 mm on imaging and no parametrial involvement. She underwent primary surgical treatment with bilateral pelvic lymphadenectomy and radical hysterectomy (in 2015), with a postoperative stage of IIA2 (FIGO 2018). Adjuvant treatment with external beam radiotherapy (EBRT), chemotherapy (CT), and brachytherapy (BT) was administered. She was disease-free at the time of writing this article.
Figure 2
Figure 2
Surgical specimen of a cervical bulky tumor after cut-through surgery. The image corresponds to a 39-year-old patient diagnosed with a 44 × 40 cm cervical squamous cell carcinoma. The preoperative assessment showed no evidence of parametrial invasion. However, during the radical hysterectomy procedure, the left parametrium appeared to be involved, which was later confirmed by the histopathological analysis of the surgical specimen. Despite receiving adjuvant CTRT, the patient experienced a recurrence at 14 months and ultimately passed away due to disease progression.

Similar articles

References

    1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 2024;74:229–263. doi: 10.3322/caac.21834. - DOI - PubMed
    1. Cibula D., Raspollini M.R., Planchamp F., Centeno C., Chargari C., Felix A., Fischerová D., Jahnn-Kuch D., Joly F., Kohler C., et al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer—Update 2023*. Int. J. Gynecol. Cancer. 2023;33:649–666. doi: 10.1136/ijgc-2023-004429. - DOI - PMC - PubMed
    1. Bhatla N., Aoki D., Sharma D.N., Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int. J. Gynecol. Obstet. 2021;155:28–44. doi: 10.1002/ijgo.13865. - DOI - PMC - PubMed
    1. Cervical Cancer. version 2.2024. 2024. [(accessed on 28 March 2024)]. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Available online: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf.
    1. Sedlis A., Bundy B.N., Rotman M.Z., Lentz S.S., Muderspach L.I., Zaino R.J. A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol. Oncol. 1999;73:177–183. doi: 10.1006/gyno.1999.5387. - DOI - PubMed

LinkOut - more resources